Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lung Neoplasms 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Thoracic × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡